Market Share of Asia-Pacific CDMO Industry
The Asia-Pacific CDMO Market is fragmented because of the presence of major players like Catalent Inc., Jubilant Biosys Ltd, Samsung Biologics, Boehringer Ingelheim Group, and WuXi Biologics. The other players are adopting acquisition and partnership strategies to enter the market and expand their offerings.
- February 2023: Catalent unveiled the completion of the expansion of a facility worth USD 2.2 million to its Clinical Supply in Singapore. The expansion increased the site footprint to 31,000 sq. ft, allowing the installation of 35 new UL freezers. The investment also enabled the facility to support bigger packaging campaigns with additional secondary packaging capacities for ULT products and increased capacity to process biopharmaceutical products and advanced modalities such as mRNA-based vaccines and cell and gene therapies.
- June 2023: FUJIFILM Diosynth Biotechnologies announced its intentions to enhance the commercial office in Tokyo to enhance sales support and customer service for contract development and manufacturing services catering to Biologics and Advanced Therapies, specifically targeting pharmaceutical and biotechnology firms based in Asia.
Asia-Pacific CDMO Market Leaders
-
Samsung Biologics
-
Jubilant Biosys Ltd
-
WuXi Biologics
-
Boehringer Ingelheim Group
-
Jubilant Biosys Ltd
*Disclaimer: Major Players sorted in no particular order
